Claris Lifesciences Peer Comparison

BSE: 533288

₹396.55

₹-0.25 (-0.06%)

As on 14-Mar-2018IST

Market cap

₹2,164 Cr

Revenue (TTM)

₹-- Cr

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Edit

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2,164	30,075	30,128	28,384	25,980
Revenue (₹ Cr)	14	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-0.27	414.00	288.22	-371.81	387.35
Net Margin (%)	38.83	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	73.53	104.53	--	67.27
Price-To-Book	0.74	5.97	22.44	3.55	15.06

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	--	2,708.00	314.72	6,314.90	340.61
Total Income	0.04	2,840.00	324.85	6,479.01	341.99
Total Expenditure	0.31	2,771.00	223.05	4,886.94	260.45
EBITDA	-0.31	-63.00	91.67	1,427.96	80.15
Depreciation	--	246.00	29.31	545.04	4.19
EBIT	-0.31	-309.00	62.36	882.92	75.96
Interest	0.00	249.00	9.37	163.45	5.62
Other Income	0.04	132.00	10.13	164.11	1.38
Exceptional Items	--	-142.00	--	18.23	--
Profit before Tax	-0.27	-568.00	63.12	949.05	71.73
Provision for Tax	--	-271.00	32.43	114.02	17.73
Profit after Tax	-0.27	-297.00	30.69	835.03	54.00

Liabilities (₹ Cr)

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-11.66	3,376.00	374.15	5,605.00	166.93
Minority Interest	--	383.00	0.00	--	--
Non-Current Liabilities	-5.28	496.00	52.94	2,560.38	80.29
Current Liabilities	21.45	3,121.00	111.16	2,590.70	166.04
Total Liabilities	9.79	7,746.00	538.25	10,777.71	413.27

Assets (₹ Cr)

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1.05	4,951.00	201.99	7,006.96	190.83
Current Assets	3.46	2,281.00	336.26	3,749.12	216.23
Total Assets	9.79	7,746.00	538.25	10,777.71	413.27
Total Debt*	21.01	2,332.00	93.28	2,910.19	136.64
Net Current Assets	-17.99	-840.00	225.10	1,158.42	50.19
Contingent Liabilities	13.19	639.00	30.36	29.98	0.00

Cashflow (₹ Cr)

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-0.11	-287.00	56.87	597.58	27.96
Cash Flow from Investing Activities	0.05	1,470.00	-36.45	-4,479.93	-101.21
Cash from Financing Activities	-0.01	-1,171.00	52.49	3,976.83	72.11
Net Cash Inflow / Outflow	-0.06	12.00	72.91	94.48	-1.14

Ratios

Profitability Ratios

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-2.88	-5.50	17.30	13.06	33.43
ROE (%)	0.00	-9.92	8.84	14.90	40.51
ROA (%)	-5.93	-3.93	6.36	7.76	16.74
EBIT Margin (%)	--	2.55	32.35	25.21	23.94
Net Margin (%)	-661.02	-10.46	9.45	12.89	15.79
Cash Profit Margin (%)	--	-1.10	19.06	19.71	17.08

Growth Ratios

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	--	-4.78	19.65	0.00	42.13
EBIT Growth (%)	72.62	-56.28	3.17	--	85.90
Net Profit Growth (%)	94.55	-115.30	-37.89	0.00	96.57
EPS Growth (%)	94.56	1,097.71	-37.89	0.00	-34.47
Book Value Growth (%)	-2.40	26.74	8.89	0.00	51.79

Valuation Ratios

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	6.12	0.00	0.00	0.00
Price / Book Value	0.00	1.36	0.00	0.00	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-275.51	95.62	0.14	2.20	2.03
Market Cap (₹ Cr)	--	4,557.85	0.00	0.00	0.00

Solvency Ratios

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-1.80	0.70	0.26	0.52	0.85
Short term debt to equity ratio	-1.80	0.32	0.12	0.06	0.27
Current Ratio	0.16	0.73	3.02	1.45	1.30
Quick Ratio	0.16	0.47	2.46	0.97	0.94
Interest Coverage	-681.50	-1.28	7.74	6.81	13.77

Operating Efficiency Ratios

	Claris Lifesciences	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	--	33.90	43.28	24.94	35.43
Asset Turnover	0.00	0.61	0.65	0.65	1.06
Receivable days	--	85.04	160.21	82.08	94.89
Inventory Days	--	59.63	58.00	64.21	60.39
Payable days	--	255.87	183.24	162.72	138.36
Cash Conversion Cycle	--	-111.19	34.97	-16.42	16.92